Unimolecular dual GLP-1R/GCGR agonist balanced receptor profile distinct from GLP-1 mono-agonists and GLP-1/GIP dual agonists Oxyntomodulin-based backbone naturally derived structural scaffold with endogenous GLP-1R/GCGR dual activity Ki 17.7 nM at human GCGR and 28.6 nM at human GLP-1R reference binding data from MedChemExpress Long-acting fatty acid lipidation albumin binding for extended receptor engagement in experimental models First dual GLP-1R/GCGR agonist to complete Phase 3 and receive regulatory acceptance GLORY program (China) Studied alongside GLP-1 mono-agonists (Semaglutide) and triple agonists (Retatrutide) for comparative receptor pathway biology Lyophilized format ensures stability and reproducibility across experimental runs Batch and lot identifiers on all labeling for full laboratory documentation compliance Research Background Mazdutide was originally developed by Eli Lilly as LY3305677 and subsequently licensed to Innovent Biologics for development as IBI362
Sleep (The Ultimate Healing Peptide) During deep sleep, your body releases: Growth hormone (natural peptide) IGF-1 (insulin-like growth factor peptide) Prolactin (tissue repair) Optimize: 7-9 hours nightly Consistent sleep/wake times Dark, cool room No screens 1 hour before bed This is FREE and scientifically proven
The studied figure of ~1,485 mcg for a 70 kg adult was a slow intravenous injection given in a sleep laboratory under polygraphic monitoring it has never been administered subcutaneously to a human in any published study, and rendering it as a number of units on an insulin syringe would convert a monitored hospital procedure into an at-home target it was never validated as
They treat the surface but fail to trigger the protein creation that drives cell regeneration from within
The most well-known copper peptide, GHK-Cu, was discovered in the 1970s and offers a wide range of benefits for skin health
